Froedtert Hospital & Medical College of Wisconsin
Welcome,         Profile    Billing    Logout  
 28 Trials 
213 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Nirav R
THRIVE, NCT05346588: Feasibility Trial

Completed
3
300
US
Anesthetic technique Propofol TIVA, Propofol TIVA, Anesthetic technique inhaled agent, Inhaled agent
Washington University School of Medicine, University of Michigan, University of Pennsylvania, Stanford University, Patient-Centered Outcomes Research Institute
Surgery--Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia Emergence Delirium, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Nausea, Postoperative, Anesthesia Morbidity, Depression, Sleep Disorders, Circadian Rhythm
04/23
06/23
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Completed
3
1453
US
Placebo, Montelukast
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
07/23
01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
3
10956
US
Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
04/24
04/24
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Completed
3
3214
US
Placebo, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
06/24
11/24
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
3
300
RoW
Tafenoquine, Primaquine, Chloroquine
GlaxoSmithKline
Malaria, Vivax
07/26
07/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II

Completed
2/3
20
US
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University
Heart Failure
10/21
10/21
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
RECOVER-AUTO, NCT06305780: NOMIC Platform Protocol

Recruiting
2
380
US
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Kanecia Obie Zimmerman
Long COVID, Long Covid19, Long Covid-19
12/25
03/26
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Completed
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
12/25
12/25
NCT03943901: Split-Dose R-CHOP for Older Adults with DLBCL

Active, not recruiting
2
26
US
Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim
University of Wisconsin, Madison, Medical College of Wisconsin
Diffuse Large B Cell Lymphoma, DLBCL, Cancer
01/25
02/27
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
31
US
Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim
Medical College of Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
06/28
12/29
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
05/26
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Active, not recruiting
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
NCT05202782: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Active, not recruiting
2
24
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
Northwestern University, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
10/26
10/29
PRO00037171, NCT04186520: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Recruiting
1/2
100
US
8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
Medical College of Wisconsin
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
06/26
06/28
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Recruiting
1
30
US
KPG-818, KPG-818 capsules
Kangpu Biopharmaceuticals, Ltd.
Hematological Malignancies
10/24
05/25
NCT05990465: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Recruiting
1
12
US
Pirtobrutinib, Jaypirca, LOXO-305, LV20.19 CAR T cells
Medical College of Wisconsin
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
07/26
07/27
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Terminated
1
4
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biotec, Inc.
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
01/24
01/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT04993287: The Cascade Feasibility Pilot (HF) Phase 3

Completed
N/A
54
US
Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Endeavor Health
Heart Failure
03/23
09/23
NCT05548218: Care Companion Diabetes

Completed
N/A
18
US
Automated health education using a digital health pathway
NorthShore University HealthSystem
Type 2 Diabetes
11/23
12/23
NCT05048329: The Cascade Feasibility Pilot (Ileostomy)

Completed
N/A
11
US
Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem
Ileostomy; Complications, Ileostomy - Stoma
05/22
08/22
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments

Active, not recruiting
N/A
8000
US
Medtronic - MITG
Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
03/25
04/25
NCT03375619: Long-term Follow-up Study of Patients Receiving CAR-T Cells

Recruiting
N/A
500
US
Long-Term Follow-Up of Participants who Received CAR-T cells
Medical College of Wisconsin
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
01/35
01/35
Bovi, Joseph A
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
NRG-BN013, NCT06500455: Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Recruiting
3
269
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fractionated Stereotactic Radiation Therapy, Fractionated Stereotactic Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
NRG Oncology, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
06/28
06/28
NRG-BN009, NCT04588246: Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Terminated
3
19
US
Memantine, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
NRG Oncology, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
08/24
08/24
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease

Active, not recruiting
3
242
Canada, US
Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/26
03/28
NRG-CC009, NCT04804644: Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Recruiting
3
200
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Memantine Hydrochloride, Ebixia, Namenda, Neurocognitive Assessment, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
NRG Oncology, National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
07/28
07/30
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NCT04155034: S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Recruiting
3
668
Canada, US, RoW
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prophylactic Cranial Irradiation, PCI
SWOG Cancer Research Network, National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
11/25
11/27
NRG-BN012, NCT05438212: Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Recruiting
3
236
Canada, US
Brain Surgery, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/27
03/27
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
163
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Observation, observation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Grade 2 Meningioma, Intracranial Meningioma
06/27
06/27
NCT04545814: Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases

Completed
N/A
11
US
Stereotactic Radiosurgery, SRS
Medical College of Wisconsin
Brain Metastases
08/24
08/24
Connelly, Jennifer M
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
163
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Observation, observation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Grade 2 Meningioma, Intracranial Meningioma
06/27
06/27
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04319276: Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Recruiting
1
36
US
Gallium maltolate (500 mg), Chemical Abstracts Service (CAS) 108560-70-9, Gallium maltolate (1,000 mg), CAS 108560-70-9, Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose)
Medical College of Wisconsin
Glioblastoma
02/25
10/25
NCT03297125: Assessment of Optune Therapy for Patients with Newly Diagnosed Glioblastoma Using Advanced MRI

Recruiting
N/A
60
US
Standard Magnetic Resonance Imaging (MRI), Advanced MRI.
Medical College of Wisconsin
Glioblastoma
07/25
07/25
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
09/25
05/27
Chaudhary, Lubna
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
PRO30178, NCT03219476: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Completed
2
37
US
Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin, Tamoxifen, Soltamox
Medical College of Wisconsin
Breast Cancer, Invasive Breast Cancer
02/20
03/25
NCT04243616: Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Active, not recruiting
2
36
US
Cemiplimab, Libtayo, Paclitaxel, Taxol, Abraxane, Carboplatin (not mandatory), Paraplatin, Doxorubicin, Lipodox, Lipodox 50, Doxil, Cyclophosphamide, cytophosphane, Cytoxan, Neosar
Medical College of Wisconsin
Invasive Breast Cancer
07/25
08/25
MAPPER, NCT06361940: Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer

Recruiting
2
100
US
Aromatase inhibitors or tamoxifen
Medical College of Wisconsin
Breast Cancer
12/28
12/29
LYL797-101, NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors

Active, not recruiting
1
100
US
LYL797
Lyell Immunopharma, Inc.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
12/25
12/26
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
52
US
Oxybutynin, Gelnique, Placebo
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Completed
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
07/24
12/24
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Active, not recruiting
4
393
Europe, Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
03/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Active, not recruiting
4
214
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
01/25
11/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
AbbVie, AbbVie Inc.
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Completed
3
1319
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Completed
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1095
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
11/37
11/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Completed
3
438
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
02/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Completed
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
09/24
09/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
920
Europe, Canada, Japan, US, RoW
Dupilumab, Dupixent®, Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
08/24
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Active, not recruiting
3
202
US
BOTOX, OnabotulinumtoxinA, Placebo
AbbVie
Masseter Muscle Prominence
12/25
12/25
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
Canada, Japan, US, RoW
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/25
03/26
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Completed
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
120
Europe, US, RoW
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
12/26
12/26
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
320
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Epkinly, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Genmab
Diffuse Large B-Cell Lymphoma
01/28
01/28
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Data readout from P3 TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for r/r myelofibrosis (based on TRANSFORM-2 trial)
Active, not recruiting
3
330
Europe, Canada, Japan, US, RoW
Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
12/26
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Recruiting
3
675
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab
AbbVie
Atopic Dermatitis
07/30
07/30
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
06/27
09/27
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed
3
150
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
10/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Completed
3
161
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
10/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Active, not recruiting
3
123
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
08/25
09/25
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
03/29
06/30
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Recruiting
3
438
RoW
YL201, topotecan hydrochloride for injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Small Cell Lung Cancer
12/27
12/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Active, not recruiting
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
04/25
04/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Completed
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
09/24
09/24
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
400
RoW
YL201, Docetaxel, Capecitabine, Gemcitabine
MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma
12/27
12/28
NCT06806293: Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
430
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Menstrual Migraine (MM)
02/27
07/27
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Active, not recruiting
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Active, not recruiting
3
1399
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
01/28
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
03/28
03/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Recruiting
3
156
Europe, Canada
ELAPR002f Injectable Gel, Saline Active Control
AbbVie
Atrophic Acne Scars
02/26
02/26
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Active, not recruiting
3
310
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting
3
480
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
09/25
08/26
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shah, Nirav R
THRIVE, NCT05346588: Feasibility Trial

Completed
3
300
US
Anesthetic technique Propofol TIVA, Propofol TIVA, Anesthetic technique inhaled agent, Inhaled agent
Washington University School of Medicine, University of Michigan, University of Pennsylvania, Stanford University, Patient-Centered Outcomes Research Institute
Surgery--Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia Emergence Delirium, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Nausea, Postoperative, Anesthesia Morbidity, Depression, Sleep Disorders, Circadian Rhythm
04/23
06/23
NCT05894577: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm F (Montelukast)

Completed
3
1453
US
Placebo, Montelukast
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
07/23
01/24
NCT04885530: ACTIV-6: COVID-19 Study of Repurposed Medications

Completed
3
10956
US
Ivermectin, Ivermectin Tablets, Fluvoxamine, Fluvoxamine Maleate Tablets, Fluticasone, Fluticasone Furoate, Placebo, Montelukast, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
04/24
04/24
NCT06042855: ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)

Completed
3
3214
US
Placebo, Metformin
Susanna Naggie, MD, National Center for Advancing Translational Sciences (NCATS), Vanderbilt University Medical Center
Covid19
06/24
11/24
REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Terminated
3
409
Europe, US, RoW
Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo
Dompé Farmaceutici S.p.A
Infectious Pneumonia, Severe COVID-19
09/24
09/24
NCT06666491: An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older

Recruiting
3
300
RoW
Tafenoquine, Primaquine, Chloroquine
GlaxoSmithKline
Malaria, Vivax
07/26
07/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT04738279: The CASCADE HF Soft Launch and Calibration Phase I and II

Completed
2/3
20
US
Non-Invasive Continuous Remote Patient Monitoring, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem, physIQ, Inc., Carnegie Mellon University, Northwestern University
Heart Failure
10/21
10/21
RESOLUTION, NCT04417257: Study of LAU-7b for the Treatment of COVID-19 Disease in Adults

Completed
2/3
125
Canada, US
LAU-7b, fenretinide, Placebo oral capsule
Laurent Pharmaceuticals Inc.
COVID-19 Disease
02/24
05/24
RECOVER-AUTO, NCT06305780: NOMIC Platform Protocol

Recruiting
2
380
US
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Kanecia Obie Zimmerman
Long COVID, Long Covid19, Long Covid-19
12/25
03/26
RECOVER-VITAL, NCT05595369: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms

Completed
2
964
US
Experimental: Paxlovid 25 day dosing, Experimental: Paxlovid 15 day dosing, Placebo Comparator: Control
Kanecia Obie Zimmerman
Long COVID, Long Covid19
08/24
03/25
NCT06404086: RECOVER-SLEEP: Platform Protocol

Recruiting
2
1074
US
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo, Melatonin, Melantonin Placebo, Tailored lighting (TL) Active, Tailored lighting (TL) Placebo
Duke University
Long COVID, Long COVID-19, Hypersomnia, Sleep Disturbance
12/25
12/25
NCT03943901: Split-Dose R-CHOP for Older Adults with DLBCL

Active, not recruiting
2
26
US
Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Prednisone, Pegfilgrastim, filgrastim
University of Wisconsin, Madison, Medical College of Wisconsin
Diffuse Large B Cell Lymphoma, DLBCL, Cancer
01/25
02/27
NCT06594939: Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma

Not yet recruiting
2
31
US
Polatuzumab Vedotin, Polivy, Mosunetuzumab, Lunsumio, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Prednisone, Pegfilgrastim, filgrastim
Medical College of Wisconsin
Diffuse Large B Cell Lymphoma (DLBCL)
06/28
12/29
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
284
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
01/26
05/26
FIRCE-1, NCT05972720: A Phase 2 Study of Firi-cel in Patients with Relapsed/refractory Large B-cell Lymphoma

Active, not recruiting
2
101
US
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
CARGO Therapeutics
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
09/25
12/26
NCT05202782: Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Active, not recruiting
2
24
US
Chimeric Antigen Receptor T-Cell Therapy, CAR T Infusion, CAR T Therapy, CAR T-cell Therapy, Chimeric Antigen Receptor T-cell Infusion, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Zanubrutinib, BGB-3111, Brukinsa, BTK-InhB
Northwestern University, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma With IRF4 Rearrangement, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
10/26
10/29
PRO00037171, NCT04186520: CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Recruiting
1/2
100
US
8/12-Day Production of Car-T Cells, 8/12-Day Production of Cryopreserved Car-T Cells, 12-Day Production of Car-T Cells
Medical College of Wisconsin
Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma
06/26
06/28
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
PBCAR0191-01, NCT03666000: Dose-escalation, Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Patients with R/r NHL and R/r B-cell ALL

Recruiting
1
129
US, RoW
Azer-cel, Allogeneic Anti-CD19 CAR T cells, PBCAR0191, Fludarabine, Cyclophosphamide, IL-2, Bendamustine
Imugene Limited
Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia
06/25
06/27
NCT04283097: Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

Recruiting
1
30
US
KPG-818, KPG-818 capsules
Kangpu Biopharmaceuticals, Ltd.
Hematological Malignancies
10/24
05/25
NCT05990465: LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

Recruiting
1
12
US
Pirtobrutinib, Jaypirca, LOXO-305, LV20.19 CAR T cells
Medical College of Wisconsin
Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma
07/26
07/27
NCT05094206: CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

Terminated
1
4
US
0.75x10^6 cells/kg CAR20.19.22 cells, 1x10^6 cells/kg CAR20.19.22 cells, 2.5x10^6 cells/kg CAR20.19.22 cells, 5x10^6 cells/kg CAR20.19.22 cells, Dose expansion: The maximum tolerated dose of CAR20.19.22 cells
Medical College of Wisconsin, Miltenyi Biotec, Inc.
B-cell Non Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia
01/24
01/24
C1763102, NCT05602363: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma

Recruiting
1
120
US
Docirbrutinib, AS-1763
Carna Biosciences, Inc.
B-cell Malignancy, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
09/27
09/27
NCT04993287: The Cascade Feasibility Pilot (HF) Phase 3

Completed
N/A
54
US
Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
Endeavor Health
Heart Failure
03/23
09/23
NCT05548218: Care Companion Diabetes

Completed
N/A
18
US
Automated health education using a digital health pathway
NorthShore University HealthSystem
Type 2 Diabetes
11/23
12/23
NCT05048329: The Cascade Feasibility Pilot (Ileostomy)

Completed
N/A
11
US
Non-invasive continuous remote monitoring with structured escalation pathway, Affective Analysis of Participant Response to Continuous Remote Patient Monitoring
NorthShore University HealthSystem
Ileostomy; Complications, Ileostomy - Stoma
05/22
08/22
NCT06404047: RECOVER-ENERGIZE Platform Protocol

Recruiting
N/A
660
US
Personalized Cardiopulmonary Rehabilitation, Structured Pacing, Education, Usual Care
Duke University, National Heart, Lung, and Blood Institute (NHLBI)
Long COVID, Long Covid19, Long Covid-19
10/25
01/26
SODA, NCT03771508: Prospective Collection of PillCam SB3 Videos and Raw Data Files for Future Developments

Active, not recruiting
N/A
8000
US
Medtronic - MITG
Small Intestine Disease, Small Intestine Cancer, Small Intestinal Ulcer Bleeding, Small Intestine Obstruction, Small Intestine Adenocarcinoma, Small Intestine Polyp
03/25
04/25
NCT03375619: Long-term Follow-up Study of Patients Receiving CAR-T Cells

Recruiting
N/A
500
US
Long-Term Follow-Up of Participants who Received CAR-T cells
Medical College of Wisconsin
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma, Central Nervous System Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, Multiple Myeloma
01/35
01/35
Bovi, Joseph A
NCT03550391: Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

Recruiting
3
206
Canada, US
Memantine, Hippocampal-avoidant (HA-WBRT) Radiotherapy, Stereotactic Radiosurgery (SRS)
Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, NRG Oncology
Brain Metastases
06/27
12/27
NRG-BN013, NCT06500455: Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

Recruiting
3
269
US
Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fractionated Stereotactic Radiation Therapy, Fractionated Stereotactic Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
NRG Oncology, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
06/28
06/28
NRG-BN009, NCT04588246: Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

Terminated
3
19
US
Memantine, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
NRG Oncology, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Brain Neoplasm, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
08/24
08/24
NCT04114981: Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery in Treating Patients with Resected Metastatic Brain Disease

Active, not recruiting
3
242
Canada, US
Single Fraction Stereotactic Radiosurgery, Stereotactic Radiosurgery, Fractionated Stereotactic Radiosurgery, Quality-of-Life Assessment, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/26
03/28
NRG-CC009, NCT04804644: Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Recruiting
3
200
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Memantine Hydrochloride, Ebixia, Namenda, Neurocognitive Assessment, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery, Whole-Brain Radiotherapy, WBRT, whole-brain radiation therapy
NRG Oncology, National Cancer Institute (NCI)
Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
07/28
07/30
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NCT04155034: S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer

Recruiting
3
668
Canada, US, RoW
Magnetic Resonance Imaging, Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Prophylactic Cranial Irradiation, PCI
SWOG Cancer Research Network, National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma
11/25
11/27
NRG-BN012, NCT05438212: Comparing the Addition of Radiation Either Before or After Surgery for Patients With Brain Metastases

Recruiting
3
236
Canada, US
Brain Surgery, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery, SRS, Stereotactic External Beam Irradiation, stereotactic external-beam radiation therapy, Stereotactic Radiation Therapy, Stereotactic Radiotherapy, stereotaxic radiation therapy, stereotaxic radiosurgery
NRG Oncology, National Cancer Institute (NCI)
Metastatic Malignant Neoplasm in the Brain
03/27
03/27
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
163
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Observation, observation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Grade 2 Meningioma, Intracranial Meningioma
06/27
06/27
NCT04545814: Analyzing Preoperative Stereotactic Radiosurgery With Gamma Knife Icon for Brain Metastases

Completed
N/A
11
US
Stereotactic Radiosurgery, SRS
Medical College of Wisconsin
Brain Metastases
08/24
08/24
Connelly, Jennifer M
NCT00887146 / 2008-007295-14: Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma

Active, not recruiting
3
305
Europe, Canada, US
concomitant temozolomide (TMZ), radiotherapy, procarbazine, adjuvant temozolomide (TMZ), CCNU, vincristine
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), European Organisation for Research and Treatment Center (EORTC), Canadian Cancer Trials Group
Brain and Central Nervous System Tumors
10/25
10/25
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
163
Canada, Japan, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Clinical Observation, observation, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Proton Beam Radiation Therapy, External beam radiation therapy protons (procedure), External Beam Radiotherapy (protons), PBRT, Proton, Proton EBRT, Proton External Beam Radiotherapy, Proton Radiation Therapy, PROTON Therapy, Radiation, Proton Beam, Quality-of-Life Assessment, Quality of Life Assessment
NRG Oncology, National Cancer Institute (NCI)
Grade 2 Meningioma, Intracranial Meningioma
06/27
06/27
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
NCT04319276: Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma

Recruiting
1
36
US
Gallium maltolate (500 mg), Chemical Abstracts Service (CAS) 108560-70-9, Gallium maltolate (1,000 mg), CAS 108560-70-9, Gallium maltolate (1,500 mg), Gallium maltolate (2,000 mg), Gallium maltolate (2,500 mg), Gallium maltolate (recommended phase 2 dose)
Medical College of Wisconsin
Glioblastoma
02/25
10/25
NCT03297125: Assessment of Optune Therapy for Patients with Newly Diagnosed Glioblastoma Using Advanced MRI

Recruiting
N/A
60
US
Standard Magnetic Resonance Imaging (MRI), Advanced MRI.
Medical College of Wisconsin
Glioblastoma
07/25
07/25
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

Recruiting
N/A
146
US
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Gliosarcoma, Recurrent Glioblastoma
09/25
05/27
Chaudhary, Lubna
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Calendar Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer
Recruiting
3
1031
Canada, US
Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.
Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma
01/28
05/35
PRO30178, NCT03219476: Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Completed
2
37
US
Anastrozole, Arimidex, Letrozole, Femara, Exemestane, Aromasin, Tamoxifen, Soltamox
Medical College of Wisconsin
Breast Cancer, Invasive Breast Cancer
02/20
03/25
NCT04243616: Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer

Active, not recruiting
2
36
US
Cemiplimab, Libtayo, Paclitaxel, Taxol, Abraxane, Carboplatin (not mandatory), Paraplatin, Doxorubicin, Lipodox, Lipodox 50, Doxil, Cyclophosphamide, cytophosphane, Cytoxan, Neosar
Medical College of Wisconsin
Invasive Breast Cancer
07/25
08/25
MAPPER, NCT06361940: Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer

Recruiting
2
100
US
Aromatase inhibitors or tamoxifen
Medical College of Wisconsin
Breast Cancer
12/28
12/29
LYL797-101, NCT05274451: A Study to Investigate LYL797 in Adults With Solid Tumors

Active, not recruiting
1
100
US
LYL797
Lyell Immunopharma, Inc.
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
12/25
12/26
Coordinator, Site
NCT05069597: Study to Evaluate Symptoms of Exocrine Pancreatic Insufficiency in Adult Participants With Cystic Fibrosis or Chronic Pancreatitis Treated With Creon

Completed
4
30
US
CREON, Pancrelipase
AbbVie
Cystic Fibrosis, Chronic Pancreatitis
07/23
08/23
NCT05647551: A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections

Completed
4
73
Europe, RoW
BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine, Juvéderm® VOLUMA® with Lidocaine
AbbVie
Facial Corrections, Facial Lines
10/23
10/23
NCT01192568: Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder

Completed
4
52
US
Oxybutynin, Gelnique, Placebo
AbbVie
Overactive Detrusor, Neurogenic Bladder
08/23
10/23
NCT06218251: A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines

Completed
4
100
Canada, US
BOTOX, Botulinum Toxin Type A, OnabotulinumtoxinA
AbbVie
Upper Facial Lines
07/24
12/24
IMMpactful, NCT06333860: A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)

Active, not recruiting
4
393
Europe, Canada, US, RoW
Risankizumab, Deucravacitinib
AbbVie
Moderate Plaque Psoriasis
03/25
03/26
NCT05969223: Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis

Active, not recruiting
4
214
US
Risankizumab, Skyrizi, ABBV-066, Placebo for Risankizumab
AbbVie
Genital Psoriasis, Scalp Psoriasis
01/25
11/25
Flex-Up, NCT05507580 / 2022-000434-42: A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
4
461
Europe, Canada, Japan, RoW
Upadacitinib, RINVOQ, ABT-494
AbbVie, AbbVie Inc.
Atopic Dermatitis
07/24
08/24
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

Completed
3
426
Europe, Canada, US
OnabotulinumtoxinA, BOTOX, Placebo
AbbVie, AbbVie Inc.
Platysma Prominence
06/23
06/23
NCT05139121: Study of the Safety and Efficacy of MR-100A-01 in Approximately 1200 Healthy Women for up to 13 Cycles

Completed
3
1319
Canada, US
MR-100A-01, Transdermal contraceptive delivery system
Mylan Technologies Inc., Mylan Inc.
Contraception
01/25
01/25
NCT02814916 / 2014-005281-30: Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Completed
3
199
Europe, US, RoW
Dalbavancin, Xydalba, Vancomycin, Oxacillin, Flucloxacillin, Cefadroxil, Clindamycin
AbbVie
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
01/24
01/24
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants

Completed
3
140
RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Forehead Lines
09/24
09/24
EPCORE FL-2, NCT06191744: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Recruiting
3
1095
Europe, Canada, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, GEN3013, Epkinly, Prednisone, Rituximab, Lenalidomide, Doxorubicin, Vincristine, Cyclophosphamide, Obinutuzumab, Bendamustine
Genmab, AbbVie
Follicular Lymphoma (FL)
11/37
11/37
SELECT-GCA, NCT03725202 / 2017-003978-13: A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Jan 2024 - Dec 2024: Regulatory submission for giant cell arteritis
Jan 2024 - Dec 2024: Data readout from SELECT-GCA trial for giant cell arteritis
Checkmark Initiation of P3 trial in giant cell arteritis
Feb 2019 - Feb 2019: Initiation of P3 trial in giant cell arteritis
Checkmark Trial initiation
More
Completed
3
438
Europe, Canada, Japan, US, RoW
Upadacitinib, ABT-494, RINVOQ, Corticosteroid (CS), Placebo
AbbVie
Giant Cell Arteritis (GCA)
02/24
02/25
NCT04903626 / 2020-005777-27: Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Completed
3
286
Europe, Canada, US, RoW
Glecaprevir/Pibrentasvir (GLE/PIB), ABT-493/ABT-530, Mavyret
AbbVie
Hepatitis C Virus (HCV)
09/24
09/24
Level Up, NCT05601882 / 2022-002482-15: A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Completed
3
920
Europe, Canada, Japan, US, RoW
Dupilumab, Dupixent®, Upadacitinib, ABT-494, RINVOQ
AbbVie, AbbVie Inc.
Atopic Dermatitis
03/24
08/24
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence

Active, not recruiting
3
202
US
BOTOX, OnabotulinumtoxinA, Placebo
AbbVie
Masseter Muscle Prominence
12/25
12/25
NCT06158841: Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

Recruiting
3
380
Europe, Canada, Japan, US, RoW
Etentamig, ABBV-383, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
AbbVie
Multiple Myeloma
12/27
12/27
Switch-Up, NCT06389136: A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Recruiting
3
300
Canada, Japan, US, RoW
Upadacitinib Dose A, ABT-494, RINVOQ, Dupilumab Dose A, Upadacitinib Dose B
AbbVie
Atopic Dermatitis
08/25
03/26
NCT06468228: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

Recruiting
3
1280
Europe, Canada, Japan, US, RoW
Lutikizumab, ABT-981, Placebo
AbbVie
Hidradenitis Suppurativa
12/26
12/26
NCT05028569 / 2021-001979-16: Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Hourglass Jan 2023 - Dec 2023 : Data from trial for episodic migraine
Completed
3
775
Europe, Canada, US, RoW
BOTOX, Botulinum Toxin Type A, Placebo
AbbVie
Episodic Migraine
11/24
11/24
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
120
Europe, US, RoW
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
12/26
12/26
EPCORE DLBCL-4, NCT06508658: A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recruiting
3
320
Europe, Japan, US, RoW
Epcoritamab, ABBV-GMAB-3013, Epkinly, Rituximab, Lenalidomide, Oxaliplatin, Gemcitabine
Genmab
Diffuse Large B-Cell Lymphoma
01/28
01/28
TRANSFORM-2, NCT04468984 / 2020-000557-27: Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

Hourglass Jan 2024 - Dec 2024 : Data readout from P3 TRANSFORM-2 trial in combination with ruxolitinib for r/r myelofibrosis
Hourglass Jan 2024 - Dec 2024 : Regulatory submission for r/r myelofibrosis (based on TRANSFORM-2 trial)
Active, not recruiting
3
330
Europe, Canada, Japan, US, RoW
Navitoclax, Ruxolitinib, Best Available Therapy (BAT)
AbbVie
Myelofibrosis (MF)
01/25
12/26
Start Up, NCT06461897: A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Recruiting
3
675
Europe, Canada, US, RoW
Upadacitinib, ABT-494, RINVOQ®, RINVOQ LQ, Dupilumab
AbbVie
Atopic Dermatitis
07/30
07/30
UBRO MM, NCT06417775: Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
450
US
Ubrogepant, UBRELVY, Placebo for Ubrogepant
AbbVie
Migraine
06/27
09/27
NCT05316220: A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

Not yet recruiting
3
80
US
Mesalamine, Delzicol, Placebo
AbbVie
Ulcerative Colitis (UC)
07/26
07/26
LINZESS, NCT04026113 / 2019-001500-38: Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

Completed
3
438
Europe, Canada, US, RoW
Linaclotide, Placebo
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
05/24
05/24
OptIMMize-1, NCT04435600 / 2019-004141-32: A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

Completed
3
150
Europe, Canada, Japan, US
Risankizumab, SKYRIZI, ABBV-066, Ustekinumab
AbbVie
Psoriasis
02/24
10/24
NCT05439616: Study of Cariprazine Oral Capsules or Solution to Assess Adverse Events and Change in Irritability Due to Autism Spectrum Disorder (ASD) in Participants Aged 5-17 Years With ASD

Completed
3
161
US
Cariprazine, VRAYLAR, AGN-241780, Placebo
AbbVie
Autism Spectrum Disorder
10/24
10/24
NCT05652205: A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Active, not recruiting
3
123
Europe, US
Linaclotide, Placebo for Linaclotide
AbbVie, Ironwood Pharmaceuticals, Inc.
Functional Constipation (FC), Chronic Idiopathic Constipation (CIC)
08/25
09/25
ELARIS EM-COC, NCT04333576: Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting
3
800
US
Elagolix, ABT-620, Orilissa, Placebo, Combined Oral Contraceptive
AbbVie
Endometriosis
03/29
06/30
NCT06612151: A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Recruiting
3
438
RoW
YL201, topotecan hydrochloride for injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Small Cell Lung Cancer
12/27
12/30
NCT05216263: Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine

Active, not recruiting
3
75
US
Atogepant, QULIPTA
AbbVie
Chronic Migraine
04/25
04/25
NCT05316233: A Study to Assess Adverse Events and Change in Disease Activity of JUVÉDERM® VOLITE™ XC Injectable Gel for Change in Neck Appearance in Adult Participants

Completed
3
159
US
VOLITE XC, JUVÉDERM® VOLITE™ XC
AbbVie
Neck Lines
09/24
09/24
NCT06629597: A Phase III Study of YL201 in Recurrent or Metastatic Nasopharyngeal Carcinoma

Recruiting
3
400
RoW
YL201, Docetaxel, Capecitabine, Gemcitabine
MediLink Therapeutics (Suzhou) Co., Ltd.
Nasopharyngeal Carcinoma
12/27
12/28
NCT06806293: Study of Oral Atogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

Recruiting
3
430
Europe, Japan, RoW
Atogepant, Qulipta, Aquipta, Placebo for Atogepant
AbbVie
Menstrual Migraine (MM)
02/27
07/27
NCT05452070: A Study to Assess Adverse Events and Change in Disease Activity of HArmonyCa Lidocaine Injectable Gel for Mid Face Soft Tissue Augmentation in Adult Participants

Active, not recruiting
3
171
Europe, Canada
HArmonyCa Lidocaine Injectable Gel
Allergan
Mid Face Volume Deficit
05/25
05/25
Up-AA, NCT06012240: A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Active, not recruiting
3
1399
Europe, Canada, Japan, US, RoW
Upadacitinib, Rinvoq, ABT-494, Placebo
AbbVie
Alopecia Areata
01/28
01/28
TeliMET NSCLC-01, NCT04928846 / 2021-001811-94: A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Recruiting
3
698
Europe, Canada, Japan, US, RoW
Telisotuzumab Vedotin, ABBV-399, Docetaxel
AbbVie
Non Small Cell Lung Cancer
03/28
03/28
NCT05995340: ELAPR002f Injectable Gel in the Treatment of Atrophic Acne Scars

Recruiting
3
156
Europe, Canada
ELAPR002f Injectable Gel, Saline Active Control
AbbVie
Atrophic Acne Scars
02/26
02/26
NCT04578756: Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder

Active, not recruiting
3
310
US
Cariprazine Flexible Dose
AbbVie
Schizophrenia, Bipolar I Disorder, Autism Spectrum Disorder (ASD)
09/25
09/25
StrataSTEPS, NCT05517902: StrataGraft Safety, Tolerability and Efficacy in Pediatric Subjects

Completed
3
1
US
StrataGraft
Stratatech, a Mallinckrodt Company, Biomedical Advanced Research and Development Authority
Skin Wound, Burns, Trauma-related Wound
05/24
05/24
NCT03850782 / 2018-002574-52: Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

Active, not recruiting
3
515
Europe, US, RoW
Bimatoprost (SR)
AbbVie
Open-Angle Glaucoma, Ocular Hypertension
08/25
08/25
NCT05411198: Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

Recruiting
3
65
US, RoW
XEN45 (Glaucoma Gel Stent)
AbbVie
Open-Angle Glaucoma
08/25
08/25
SELECT- SWITCH, NCT05814627: Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

Recruiting
3
480
Europe, Canada, Japan, US, RoW
Upadacitinib, RINVOQ, Adalimumab, Humira, Upadacitinib Matching Placebo, Adalimumab Matching Placebo
AbbVie
Rheumatoid Arthritis
09/25
08/26
DESTINY-Gastric04, NCT04704934 / 2020-004559-34: Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen

Jan 2024 - Dec 2024: Data from DESTINY-Gastric04 trial for HER2+ve gastric cancer
Jan 2024 - Dec 2024: Acceptance of regulatory submission for HER2 positive metastatic and/or unresectable gastric or gastroesophageal junction adenocarcinoma (based on DESTINY-Gastric04 trial)
Checkmark Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Jul 2021 - Jul 2021: Data from DESTINY-Gastric04 trial for HER2 Positive Gastric Cancer (GC) or GEJ at ESMO 2021
Checkmark First patient was dosed in DESTINY-Gastric04 in patients with HER2 positive gastric or GEJ adenocarcinoma
More
Active, not recruiting
3
490
Europe, Japan, RoW
Trastuzumab deruxtecan, T-DXd, DS-8201a, ENHERTU®, Ramucirumab, CYRAMZA®, Paclitaxel
Daiichi Sankyo, AstraZeneca
Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/25
02/26
 

Download Options